Isoxsuprine sandbox: Difference between revisions
(Created page with "{{DrugProjectFormSinglePage |authorTag={{SS}} |genericName=Isoxsuprine |aOrAn=a |indication=cerebral vascular insufficiency, peripheral vascular disease of arteriosclerosis...") |
No edit summary |
||
| Line 15: | Line 15: | ||
* Dosing information | * Dosing information | ||
:* '''10 to 20 mg PO tid or qid''' | :* '''10 to 20 mg PO tid or qid''' | ||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine in adult patients. | ||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine in pediatric patients. | ||
|contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding. | |contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding. | ||
|warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning. | |warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning. | ||
|clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of [[hypotension]], [[tachycardia]], [[nausea]], [[vomiting]], [[dizziness]], abdominal distress, and severe [[rash]]. If rash appears the drug should be discontinued. | |clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of [[hypotension]], [[tachycardia]], [[nausea]], [[vomiting]], [[dizziness]], abdominal distress, and severe [[rash]]. If rash appears the drug should be discontinued. | ||
Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused. | Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused. | ||
|administration=Oral | |administration=Oral | ||
|monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring. | |monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring. | ||
|IVCompat=There is limited information about the IV Compatility. | |IVCompat=There is limited information about the IV Compatility. | ||
|overdose=FDA Package Insert for | |overdose=FDA Package Insert for Isoxsuprine contains no information regarding Adverse Reactions. | ||
|drugBox={{chembox2 | |drugBox={{chembox2 | ||
| Verifiedfields = changed | | Verifiedfields = changed | ||
| Line 74: | Line 73: | ||
}} | }} | ||
}} | }} | ||
|mechAction=FDA Package Insert for | |mechAction=FDA Package Insert for Isoxsuprine contains no information regarding mechanism of action. | ||
|structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter | |structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter | ||
taste, It has a following structural formula | taste, It has a following structural formula | ||
[[File:lsoxsuprine_structure_01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | [[File:lsoxsuprine_structure_01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
|PD=FDA Package Insert for | |PD=FDA Package Insert for Isoxsuprine contains no information regarding pharmacodynamics. | ||
|PK=FDA Package Insert for | |PK=FDA Package Insert for Isoxsuprine contains no information regarding pharmacokinetics. | ||
|nonClinToxic=FDA Package Insert for | |nonClinToxic=FDA Package Insert for Isoxsuprine contains no information regarding nonclinical toxicology. | ||
|clinicalStudies=FDA Package Insert for | |clinicalStudies=FDA Package Insert for Isoxsuprine contains no information regarding clinical studies. | ||
|howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's | |howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's | ||
|alcohol=Alcohol-Isoxsuprine | |alcohol=Alcohol-Isoxsuprine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
}} | }} | ||
{{PillImage | {{PillImage | ||
Revision as of 04:16, 27 July 2014
{{DrugProjectFormSinglePage |authorTag=Sheng Shi, M.D. [1] |genericName=Isoxsuprine |aOrAn=a |indication=cerebral vascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease. |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content) |fdaLIADAdult=Cerebral Vascular Insufficiency
- Dosing information
- 10 to 20 mg PO tid or qid
Peripheral Vascular Disease
- Dosing information
- 10 to 20 mg PO tid or qid
|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Isoxsuprine in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Isoxsuprine in adult patients.
|offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Isoxsuprine in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Isoxsuprine in pediatric patients.
|contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
|warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning.
|clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears the drug should be discontinued.
Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
|administration=Oral
|monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring.
|IVCompat=There is limited information about the IV Compatility.
|overdose=FDA Package Insert for Isoxsuprine contains no information regarding Adverse Reactions.
|drugBox={{chembox2
| Verifiedfields = changed
| UNII_Ref = 
| UNII = R15UI3245N
| verifiedrevid = 444643797
|ImageFile=Isoxsuprine.png
|ImageSize=150px
|IUPACName=4-{1-hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol
|OtherNames=Vasodilian, Duvadilan
|Reference=[1]
|Section1=! colspan=2 style="background: #f8eaba; text-align: center;" |Identifiers
|-
|
|
|-
|
|
|-
| ChEMBL
|
|- | ChemSpider
|
|-
| ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |-
| KEGG
|
|- | MeSH | Isoxsuprine |-
|
|
|-
| colspan="2" |
- InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3Key: BMUKKTUHUDJSNZ-UHFFFAOYSA-N
- InChI=1/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3Key: BMUKKTUHUDJSNZ-UHFFFAOYAW
|-
| colspan="2" |
- O(c1ccccc1)CC(NC(C)C(O)c2ccc(O)cc2)C
|- |Section2=! colspan=2 style="background: #f8eaba; text-align: center;" |Properties
|-
|
| C18H23NO3
|- | Molar mass
| 301.38012
|- |Section3= }} |mechAction=FDA Package Insert for Isoxsuprine contains no information regarding mechanism of action. |structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter taste, It has a following structural formula
|PD=FDA Package Insert for Isoxsuprine contains no information regarding pharmacodynamics. |PK=FDA Package Insert for Isoxsuprine contains no information regarding pharmacokinetics. |nonClinToxic=FDA Package Insert for Isoxsuprine contains no information regarding nonclinical toxicology. |clinicalStudies=FDA Package Insert for Isoxsuprine contains no information regarding clinical studies. |howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's |alcohol=Alcohol-Isoxsuprine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. }} {{#subobject:
|Page Name=Isoxsuprine sandbox |Pill Name=No_image.jpg |Drug Name=Isoxsuprine Hydrochloride 20 MG Oral Tablet |Pill Ingred=lactose, cellulose, microcrystalline, calcium phosphate, dibasic, anhydrous, povidone k30, sodium starch glycolate type a potato, magnesium stearate|+sep=; |Pill Imprint=20;VISTA065 |Pill Dosage=20 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=10.00 |Pill Scoring=2 |Pill Image= |Drug Author=Vista Pharmaceuticals, Inc |NDC=61971-065
}}
{{#subobject:
|Label Page=Isoxsuprine sandbox |Label Name=Isoxsuprine_label_01.jpg
}}
{{#subobject:
|Label Page=Isoxsuprine sandbox |Label Name=Isoxsuprine_panel_01.png
}}